This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for HYMPAVZI®▼ (marstacimab) Prescribing Information.
Innovative mechanism of action
A human monoclonal antibody, HYMPAVZI can help to promote haemostasis in patients with either FVIII or FIX deficiency.1 HYMPAVZI targets TFPI, a natural anticoagulant and core component of the coagulation cascade1,2
Promoting haemostasis vs factor replacement
HYMPAVZI promotes blood clotting by inhibiting TFPI, increasing free FXa, and thrombin generation. It does not replace factor1
Specific K2 domain binding
HYMPAVZI inhibits TFPI by specifically binding to the K2 domain, thus helping to prevent TFPI attachment to FXa and neutralising its activity1,2
Steady-state half-life
The mean effective steady-state half-life of HYMPAVZI is estimated to be approximately 16 to 18 days1
FIX, factor IX; FVIII, factor VIII; FXa, factor Xa; K2, Kunitz 2; MOA, mechanism of action; TFPI, tissue factor pathway inhibitor.
Learn more about HYMPAVZI efficacy.
Understand the HYMPAVZI dosing schedule and see how HYMPAVZI can be administered.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.